Shanghai Asclepius Meditec Technology Co., Ltd. (hereinafter referred to as Asclepius Meditec), a rising newcomer that pivoted into the medical device sector less than 10 years ago, may not be widely known by name, yet has earned the singular attention of Academician Zhong Nanshan, whose recognition and affirmation of its hydrogen medicine achievements speak volumes. The hydrogen–oxygen nebulizer, a newly approved innovative product that has obtained China’s Class III respiratory medical device registration, not only stood out as a star innovation at the 2nd China International Import Expo, but also played an adjuvant therapeutic role at a critical juncture of the COVID-19 pandemic, earning unanimous praise from experts, physicians, and patients. Behind this success lies the lonely pain of a man confronting death, the arduous decade-long transformation of an entrepreneur, and the proactive exploration by a Chinese son of a shared human challenge—chronic disease. He is Lin Hsin-Yung, the helmsman of Asclepius Meditec—the company that created what is currently the world’s most stable and smallest hydrogen–oxygen nebulizer.
Recent photo of Lin Hsin-Yung
At around 3:00 p.m. on January 25, 2020—the afternoon of Lunar New Year’s Day in the Gengzi year—Lin Xinyong, having finally set aside work and returned to daily life, succumbed to fatigue and fell asleep. When he was awakened by the urgent and persistent vibration of his phone, he had not yet realized that during his deep sleep he had missed five emergency calls from Academician Zhong Nanshan; what awaited him was an urgent rescue tied to national lives, a sacred mission uniting personal dreams, corporate honor, and national dignity.
Seeing Academician Zhong’s name, Lin Hsin-Yung instantly woke up. It was a direct, brief, and solemn call. On the other end, Academician Zhong was attending an emergency meeting convened by central leaders to discuss responses to the rapidly escalating COVID-19 outbreak. Once connected, Academician Zhong dispensed with pleasantries and politely but directly asked about the company’s current inventory of hydrogen–oxygen nebulizers and whether overtime production could be initiated immediately. Having interacted with Academician Zhong for six years, Lin Hsin-Yung sensed the urgency and gravity in his restrained yet thorough inquiry and agreed without hesitation to book an immediate flight back to Shanghai and begin coordinating anti-epidemic supplies and the resumption of production.
Lin Xinyong accompanying Academician Zhong Nanshan on a tour of the production workshop
February 2—Lunar New Year’s Day Nine—was destined to be unforgettable for Lin Hsin-Yung. Upon the strong recommendation of Academician Zhong and through joint efforts of governments and enterprises at all levels, Asclepius Meditec’s hydrogen–oxygen nebulizer—after nine years of refinement and waiting—finally reached its defining moment: approval for market launch as a “National Innovation” Class III respiratory medical device by the National Medical Products Administration. As the news spread, employees embraced each other in tears.
After obtaining the Class III medical device registration certificate, Asclepius Meditec’s hydrogen–oxygen nebulizers set out with a clear positioning as a “secondary attacker in disease treatment” (in Academician Zhong’s words), heading in batches to the front lines of epidemic control.
On February 5, as the vanguard of the response, the first batch of 21 units was delivered to Wuhan Puren Hospital, Wuhan Hanyang Hospital, and Zhongnan Hospital of Wuhan University.
On February 7, five units were delivered to Wuhan Central Hospital.
On February 12, 403 units were delivered to medical teams aiding Jingzhou, Hubei.
On February 18, 362 units were delivered to Guangdong.
On February 26, 683 units were delivered to the Asclepius Meditec Wuhan Command Center.
On March 5, 1,000 units were delivered to the COVID-19 Prevention and Control Command Center of Wuhan East Lake High-Tech Development Zone…
After the outbreak, hydrogen–oxygen nebulizers entering production were loaded in batches and transported to the front lines
During the most critical month of the national outbreak—when Wuhan faced the greatest pressure—Asclepius Meditec coordinated with 46 medical institutions across 24 cities and counties in seven provinces nationwide, donating nearly 3,000 hydrogen–oxygen nebulizers valued at nearly RMB 200 million, contributing Shanghai’s strength to the decisive battle against COVID-19. For this outstanding performance, multiple media outlets—including Xinhua, People’s Daily Online, CCTV, China Youth Daily, Jiefang Daily, Xinmin Evening News, and Southern Daily—covered the story and gave high praise. In July 2020, at a symposium on enterprises jointly fighting COVID-19 organized by the Guangdong Provincial Health Commission, Asclepius Meditec was invited to attend and honored with the “Together Against the Epidemic” award.
This exemplary outcome was inseparable from support by governments at all levels and close coordination across all links. At the time of Academician Zhong’s request, company inventory stood at just over 30 units. The hydrogen–oxygen nebulizer comprises more than 1,000 components, with over a hundred supply-chain enterprises nationwide—most of which were shut down. Ultimately, under the coordinated mutual-support mechanism of the Yangtze River Delta (Jiangsu, Zhejiang, Anhui, and Shanghai), the supply chain was reconnected and production resumed. On February 13, Asclepius Meditec, as a key manufacturer of COVID-19 response supplies, was included in the list of “Important Epidemic Prevention Equipment” enterprises under the Medical Supplies Support Group of the State Council Joint Prevention and Control Mechanism. On March 4, the National Health Commission issued the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial, Seventh Edition), which for the first time incorporated hydrogen–oxygen mixed gas therapy, stating that “hydrogen–oxygen mixed inhalation therapy may be used when conditions permit.” Behind this decisive inclusion lies rigorous scientific evaluation and well-founded confidence.
In the decisive battle against the epidemic, Asclepius Meditec contributed Shanghai’s strength
A hydrogen–oxygen nebulizing device is a system that, through specialized processing, can extract 3 liters of gas per minute from water—comprising 66.66% hydrogen and 33.33% oxygen.When patients or users inhale the hydrogen–oxygen mixed gas via a nasal cannula, the therapy not only supplements oxygen but also enhances cellular antioxidant capacity, thereby improving cellular vitality and reducing the likelihood of systemic inflammation and viral differentiation.
In the past, when hydrogen and oxygen were mentioned together, people often reacted with apprehension, instinctively associating the combination with the risks of combustion and explosion. In this innovative endeavor, which bears directly on human quality of life and overall health indices, a fundamentally new line of thinking has emerged: hydrogen is the lightest gas in the atmosphere and has the smallest molecular size. Inhalation of hydrogen can reduce airflow resistance within the bronchial tree, improve oxygen utilization efficiency, decrease airway resistance, and thereby alleviate symptoms of dyspnea. The integration of hydrogen, oxygen, and medications can further enhance inhaled drug utilization. Previously, under the leadership of the Departments of Respiratory and Critical Care Medicine at the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Infectious Disease Hospital, and Shanghai Tenth People’s Hospital, a series of exploratory clinical treatments were conducted in observation wards. Clinical practice has demonstrated that, among patients with COVID-19 who used hydrogen–oxygen nebulizing devices during the pandemic, improvements in airway edema, mucus accumulation, and even mucus plugging were significantly more pronounced than with oxygen therapy alone.
Use of hydrogen–oxygen nebulizers at the First Affiliated Hospital of Nanchang University during the pandemic
As of 2019, more than half of the top 100 among China’s 980,000 medical institutions had substantively participated in Asclepius Meditec’s research programs. Asclepius Meditec has cumulatively published 32 high-impact SCI papers with its partner institutions; it has completed the world’s first human clinical projects, including a multicenter clinical project on allergic rhinitis and a project on lung inflammatory factors in sanitation workers exposed to PM2.5. Over the next three years, multiple human clinical studies will be carried out cumulatively, with collaboration partners covering 59 domestic teaching hospitals and more than 10 overseas teaching hospitals.
Not long ago, research findings entitled Inhalation of Hydrogen–Oxygen Mixed Gas Improves Dyspnea in Patients with COVID-19 were publicly published; this retrospective, multicenter clinical study was jointly conducted by physicians from dozens of designated COVID-19 hospitals nationwide under the leadership of Zhong Nanshan, confirming that hydrogen–oxygen mixed gas inhalation can alleviate clinical symptoms such as dyspnea and shorten hospital stays.
As early as 1992, after three years of careful evaluation, Lin Hsin-Yung finally added Shanghai as the third base of operations to his Malaysia-rooted enterprise, Zhongrong Group. Since embarking on entrepreneurship in 1977, he had always treated his body as inexhaustible capital, striving with the widely acknowledged spirit of a relentless workhorse. Despite having elevated his products to world-leading standards and built a global No. 1 brand, and despite having been forced to undergo resection of two-thirds of his stomach at the age of 19 due to life overdrafting, Lin Hsin-Yung continued to work day and night for the continuous expansion of his career. Until one summer afternoon in 2008, when his former life pattern came to an abrupt halt.
April 15–17, 2016, during the World Congress of Thoracic Diseases, Lin Hsin-Yung posed for a photo with Academician Zhong Nanshan and Professor Bai Chunxue.
It was after an important meeting that Lin Hsin-Yung suddenly began vomiting blood incessantly. He sought medical care at four hospitals in succession, all of which ruthlessly declared, “advanced gastric cancer, with at most six months to live.” Although this result was not entirely unexpected, his unyielding character made him unwilling to be cornered by fate; thinking of his beloved youngest daughter, only five or six years old, and his elderly father still alive, he knew he had to take action and “fight back” against death.
Recalling the three years of seeking medical treatment, the scenes remain vivid—“waking up each day felt joyful, fearing I might pass away in my sleep at any moment”—yet this had long surpassed fear born of ignorance about disease, and he would jokingly call it “a very ‘interesting’ experience.” Amid repeated struggles between rational acceptance of death and emotional attachment to life, Lin Hsin-Yung completed the traditional trilogy of surgery, radiotherapy, and chemotherapy, and after many turns sought treatment from Japanese oncology experts. Although the disease was brought under control, quality of life was scarcely present.
In March 2011, a turning point emerged. At that time, a major earthquake struck Japan, triggering a tsunami and a nuclear power plant leak; driven by international humanitarian concern, Lin Hsin-Yung, despite his frail condition, threw himself into relief efforts. At the disaster site, he was astonished to see local Japanese residents bathing in costly hydrogen-rich water, believing it had cancer-preventive effects. As a cancer patient who had just escaped the brink of death, he was highly sensitive to this and quickly developed an interest in molecular hydrogen.
After returning to Shanghai, Lin Hsin-Yung immediately launched an in-depth investigation. He first immersed himself in highly technical and challenging research papers on hydrogen molecular medicine, and subsequently traveled to Japan to visit the authors of those studies. Through these discussions, he learned that hydrogen molecules do indeed help enhance cellular activity and improve immune function; however, at that time, no device on the market was capable of safely and reliably generating both oxygen and hydrogen in a form suitable for human use. This gap greatly ignited his passion to benefit himself and others.
Lin Xinyong accompanied Academician Zhong Nanshan on a tour of the company headquarters, introducing the corporate culture.
Skilled in automated machinery manufacturing, Lin Hsin-Yung assembled an R&D team to work at high intensity, and within just three months developed a device that produces hydrogen via water electrolysis, which became the prototype of the hydrogen–oxygen nebulizer. The greatest difference between this device and the then-popular Japanese air-separation hydrogen methods lay in its high flow rate and high concentration, enabling production of hydrogen–oxygen mixed gas suitable for human inhalation rather than ordinary industrial gas. Although a medical outsider without formal lineage, his strong personal experience and encouraging practical results gave him the confidence to persevere and a light of hope. “I was the first beneficiary myself, and the second was my father. He developed Alzheimer’s disease in 2010 and no longer recognized me at that time. After six months of use, his cognitive function returned to normal, and he appeared revitalized and energetic. My friends around me also became my ‘guinea pigs,’ and many classic cases emerged from among them.” Thus, he longed to commercialize the product so that more people could know about it and benefit from it. This process was long. Repeated setbacks, along with the disdain and blows from professionals, were commonplace. His unyielding heart never gave up exploring every possible avenue. After many twists and turns, Lin Hsin-Yung finally obtained, on a day in 2014, an opportunity to brief Academician Zhong Nanshan. Despite thorough preparation, he was informed just minutes before the meeting that there was another meeting to attend, time was tight, and he should be brief. The originally scheduled 30-minute exchange was cut in half. After only a few sentences of explanation, Lin Hsin-Yung was interrupted; Academician Zhong Nanshan asked only three questions, indicated that he understood, and then hurried away without expressing a position. The frustration of being “brushed off” severely dampened the team’s morale and confidence, and they set off on the return journey in low spirits.
Soon afterward, Lin Hsin-Yung unexpectedly received a call from Academician Zhong’s assistant; faced with the request to “borrow several machines for experiments,” he was overjoyed, his excitement beyond words. At 2:00 p.m. on the sixteenth day of the first lunar month the following year, good news arrived from the heavens. Lin Hsin-Yung once again unexpectedly received a personal call from Academician Zhong Nanshan, who explained that due to a busy schedule he could not make a visit and instead asked Lin Hsin-Yung to fly to Guangzhou to communicate cooperation intentions as early as possible. Lin Hsin-Yung decisively boarded the earliest flight the next day and met Academician Zhong Nanshan for the second time amid the bustling crowds at Baiyun Airport. The two exchanged views centered on the hydrogen–oxygen nebulizer and the development prospects of hydrogen medicine, thus forming a mentor–student bond.
Although it was an honor to attract Academician Zhong’s attention, the years of struggle that followed remained dim. Whenever Lin Hsin-Yung recalled Academician Zhong’s words over the phone—“This is real”—and whenever he saw Academician Zhong’s hurried figure and encouraging gaze, his confidence and courage once again overwhelmed despair and helplessness.
However, the pandemic had not yet ended, and while Academician Zhong Nanshan, a guardian of the people, was still exhausting himself in the fight against COVID-19, rumors about alleged conflicts of interest between him and Asclepius Meditec spread unchecked. In response, Academician Zhong had no intention of refuting them. Lin Hsin-Yung stated that the two had always maintained a gentlemanly relationship as plain as water, and that Academician Zhong would never allow any personal feelings to be mixed into the sacred field of scientific research: “Academician Zhong is a physician; his heart holds only patients and research, and he considers the greater good of the nation—such a realm is beyond the reach of ordinary people like us.”
On November 9, 2019, at the 2nd China International Import Expo, Lin Hsin-Yung was invited to take the stage to introduce the hydrogen–oxygen nebulizer.
In 2019, the hydrogen–oxygen nebulizer achieved a fundamental breakthrough—after several failed clinical trials, it ultimately delivered successful outcomes in chronic obstructive pulmonary disease, reaching statistical significance; this achievement was, of course, inseparable from the participation of Academician Zhong Nanshan and ten leading respiratory experts in China, as well as the close collaboration of dozens of specialists including Professor Xu Kecheng, recipient of the Bethune Medical Award, and Professor Lv Youyong of Peking University, who jointly engaged in the practice and research of hydrogen-based cancer control, truly witnessing the remarkable therapeutic power of hydrogen, and co-authoring and publishing Hydrogen Gas Cancer Control: Theory and Practice, providing a phased summary of current achievements in hydrogen-based anticancer research.
With the deepening of hydrogen anticancer research, the hydrogen–oxygen nebulizer has attracted broader attention within the medical community and has also received affirmation and support from a large number of experts and scholars, including Academician Tang Zhaoyou, founder of small hepatocellular carcinoma research, Academician Wu Mengchao, regarded as the father of hepatobiliary surgery, and Academician Wang Zhenyi, pioneer of tumor-induced differentiation. This undoubtedly gave Lin Hsin-Yung tremendous encouragement and motivation; always pragmatic in enterprise management and social contribution, he bears no psychological burden over the “overnight fame” of the hydrogen–oxygen nebulizer, neither fearing competition from counterfeit devices nor worrying about technological catch-up, and for future development he has only one sentence: “If it’s the right thing, just do it.”
It is not hard to imagine how difficult it is for someone without a medical background, who also has a personal history of cancer, to claim that they can “produce gases capable of treating multiple chronic diseases” and gain trust from society—especially from medical experts—let alone with hydrogen–oxygen mixed gas. Yet Lin Hsin-Yung achieved it. This is attributable not only to his own relentless perseverance, but also to the selfless assistance of benefactors and the tireless guidance of spiritual mentors.
Academician Zhong Nanshan has provided sustained and professional guidance and oversight to Asclepius Meditec, undoubtedly serving as a “benefactor” in Lin Hsin-Yung’s career. Another figure, Master Cheng Yen, founder of the Tzu Chi Charity Foundation, played the role of a spiritual mentor on Lin Hsin-Yung’s path from failure to success.
Interior view of Asclepius Meditec’s corporate offices
Floors under construction and renovation, soon to be used as venues for conferences, training, and exchanges
Anyone who has visited Asclepius Meditec’s headquarters invariably praises its vibrant environment. This is because it is not only lush with greenery and flowing water, but also bright, clean, and spotless; not only is this true inside the company, but even within a three-kilometer radius there is hardly a piece of litter or a cigarette butt to be found. Lin Hsin-Yung’s emphasis on environmental protection has a long history; deeply distressed by today’s fast-food culture and excessive packaging, he implemented waste sorting internally many years ago, assigning environmental maintenance responsibilities to individuals.
During interviews at Asclepius Meditec, regardless of the depth of contact with employees or the extent observed, one is invariably drawn to its distinctive corporate culture: every employee, including middle and senior managers, pays only a small amount to enjoy high-quality meals provided by the company; raw ingredients are green foods grown and raised by employees themselves, instilling pride and a sense of accomplishment; meals are served buffet-style with an emphasis on zero food waste; the tradition of two vegetarian days per week is maintained; employees take turns serving as duty stewards…and there is an especially heartwarming detail: a bamboo coin tube for charitable causes is placed on each desk—“every time you put a coin in, a thought of kindness is planted.” All of these, Lin Hsin-Yung attributes to the teachings of Master Cheng Yen. Since being formally introduced to the Shanghai branch of the Tzu Chi Charity Foundation in 2010, he has incorporated many of Tzu Chi’s principles into corporate management, stating that “although we are far from perfect, we are moving in this direction.”
Over the past decade, Master Cheng Yen has given Lin Hsin-Yung two sets of teachings, profoundly shaping his present vision and outlook.
Earlier, once the prototype device was successfully developed, Lin Hsin-Yung eagerly reported the results to Master Cheng Yen. After carefully listening to his explanation, the Master offered three suggestions: first, water is the source of life—since hydrogen–oxygen mixed gas produced from purified water is harmless to humans, it is worth pursuing; second, do not rush for short-term market gains—focus first on research and take the medical pathway; third, persist, and success will come in five to ten years. Although the word “research” alone made him feel weak at the knees, Lin Hsin-Yung found courage and confidence in the first and third suggestions and resolved to persevere through all difficulties.
After several more years of intensive work, the performance of the hydrogen–oxygen nebulizer improved dramatically. Lin Hsin-Yung’s quality of life underwent a qualitative leap, and his drive toward profit also began to stir again. He joyfully brought the new-generation device to Master Cheng Yen to report the latest progress. Upon hearing the proposed price, the Master’s originally gentle expression immediately darkened: do you know how many people fall ill because they are poor, and become poor because they are ill? A device that everyone cannot afford is equivalent to not having been invented at all. It would be better to slow down and think about how to make the product cheaper, most effective, and environmentally friendly. These words filled Lin Hsin-Yung with deep shame; from that point on, he firmly remembered the Master’s teaching of “guard against greed, anger, and ignorance, and help the poor of the world,” and strictly adhered to “affordable, environmentally friendly, and most effective” as the core standards for device production.
Having escaped the boundary between life and death, entered a scarcely explored new field, and undergone multiple spiritual purifications, Lin Hsin-Yung today is not only grateful for all encounters in life but also steadfast in his commitment to dedication and contribution. His thoughts are no longer confined to running a business, but extend to the social responsibility of “not pursuing science for science’s sake, but translating science into benefits for ordinary people,” along with a heartfelt blessing of “may Heaven protect China.”
Looking back on more than 40 years of entrepreneurship, Lin Hsin-Yung is filled with emotion; he jokes that excessive toil made him age prematurely—under 60 yet looking over 70—but in exchange he gained the comfort of pioneering new horizons: “I am happy to have been part of so many people’s life journeys, saving so many families. Now every time I visit Director Xu Kecheng’s office, those patients become very emotional when they see me and say, ‘You gave us back confidence in life and living—and it didn’t even cost us money.’” Facing patients’ heartfelt gratitude, a sense of pride wells up within him. When outsiders praise his great compassion, he suddenly becomes humble: “After all, at its core it is still an enterprise; an enterprise must develop good products and then generate profits through sales. Perhaps because of my personal experience, I can better empathize with the pain of cancer patients, so if I can help many people while making money—even if it means earning a bit less—it doesn’t matter.” Within these plain words lies a life philosophy that balances rationality and humanity (emotion); in his view, grasping the balance between the two “has always been the most central proposition for a nation, an enterprise, and an individual,” and it is also a principle he will continue to uphold.
Hydrogen–Oxygen Nebulizer
The hydrogen–oxygen nebulizer produced by Asclepius Meditec is designed for broad global applicability and to meet the needs of people worldwide; this was considered from the very beginning of its design. Lin Hsin-Yung stated that, as an authentic Chinese invention, he hopes it can be incorporated into the Belt and Road Initiative, bringing health to people while promoting economic cooperation.
Regarding future corporate development, Lin Hsin-Yung’s thinking is multidimensional. As a former patient and now an innovative device developer, he deeply understands that so-called diseases—especially chronic diseases—are often burdens brought about by ignorance and desire. He calls on people to change their lifestyles, establish a correct view of life, and recognize that prevention is greater than treatment. As the operator of a medical device enterprise, from the COVID-19 outbreak to the increasing frequency of natural disasters, and looking ahead to the challenging period of China’s demographic dividend from 2030 to 2060, he has focused corporate operations on how to reduce the burden on the national medical insurance system. In the short term of three to five years, there is hope to pursue a commercial insurance pathway—buy health and receive insurance, or buy insurance and receive health benefits—for the general public. Meanwhile, the factory buildings constructed since settling in Shanghai will, after high-quality renovation, be transformed into a hydrogen medicine academy and training base, providing a platform for industry development and academic exchange.
Asclepius Meditec, verdant with greenery and flowing water
The factory and office buildings in use today are still those constructed 25 years ago when the company first settled there
From a leader in manufacturing to a medical device engineer and advocate and pioneer of molecular hydrogen medicine, Lin Hsin-Yung’s life has undergone a transformation. In his view, this is by no means the result of individual effort alone, but rather the workings of providence. Molecular hydrogen originates from water; whether it is the philosophy of “the highest good is like water” or the emerging discipline of molecular hydrogen medicine that may accelerate the grand health journey, all are gifts of nature to humanity.
“Only truth and simplicity can take one far.”
Academician Zhong Nanshan’s Evaluation of Lin Hsin-Yung
In 2019, at the launch of Hydrogen Gas Cancer Control: Theory and Practice and an academic forum on hydrogen medicine and cancer rehabilitation jointly organized by Jinan University and Yangcheng Evening News, Academician Zhong Nanshan—recipient of the Medal of the Republic, respiratory disease expert, and member of the Chinese Academy of Engineering—was unable to attend in person and therefore delivered a video message expressing confidence in the current development of molecular hydrogen medicine and expectations for its future potential: “I hope molecular hydrogen medicine, especially in cancer control, as well as in many airway diseases, neurological diseases, and future research on many systemic diseases, will apply evidence-based medicine to verify its effectiveness—that would be an innovation, a creation for the world.”
As early as 2014, Academician Zhong established a connection with Lin Hsin-Yung through molecular hydrogen medicine, affirmed the visible effects of the hydrogen–oxygen nebulizer in tumor treatment, and highly praised entrepreneur Lin Hsin-Yung’s role in advancing hydrogen medicine: “Mr. Lin has made significant academic contributions to hydrogen medicine. As logistical support and as a coordinator, his guiding philosophy has always been to contribute to humanity, especially to some intractable diseases.”
Profile
Lin Xinyong, Legal Representative and Chairman of Shanghai Asclepius Meditec Technology Co., Ltd. Since founding Zhongrong Group in 1977, he has established companies in Taiwan, Malaysia, Shanghai, Dalian, Mexico, and Nantong, operating in precision automated manufacturing. Founded Shanghai Asclepius Meditec Technology Co., Ltd. in 2011, dedicated to advancing hydrogen medicine. Serves as a director of the World Taiwanese Chambers of Commerce, the Shanghai Taiwanese Business Association, and as an honorary director of the Tzu Chi Charity Foundation, among other social roles. As of July 2020, nearly 400 patents had been applied for, with 192 patents granted domestically and internationally, including 114 invention patents, 39 utility model patents, and 39 design patents.
Authors: Deng Yun Lü Yuehua
Production: Li Peng
Editor: Fan Liqing
